NK-1 receptor antagonism decreases PONV by Kakuta, Nami et al.
INTRODUCTION
Nausea and vomiting is one of the most fre-
quently reported patient complaints following
anesthesia (1, 2). This phenomenon, known as post-
operative nausea and vomiting (PONV) is of greater
concern to patients than postoperative pain (3).
PONV occurs in approximately 30% of all patients
undergoing generalized anesthesia (4). PONV can
result in several post-surgical complications includ-
ing discomfort or pain, fluid and electrolyte imbal-
ances, surgical wound dehiscence, hemorrhage, and
aspiration pneumonia (4). PONV has four main risk
factors including : female gender, history of PONV
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or motion sickness, nonsmoking, and the use of
postoperative opioids (5). Interestingly, laparoscopic
gynecological procedures have nearly an 80% inci-
dence of PONV (6). Although the exact reasoning
is unknown it has been suggested that in addition
to the female gender risk factor that the increased
intra-abdominal pressure used during laparoscopic
procedures may be partly responsible for this dra-
matic increase in PONV (7).
Primary control of nausea and vomiting arises
from the “central pattern generator for vomiting,”
located in the medulla oblongata (8). There are five
primary afferent pathways involved in stimulating
vomiting : the chemoreceptor triggering zone, the
vagal mucosal pathway in the gastrointestinal sys-
tem, neuronal pathways from the vestibular system,
reflex afferent pathways from the cerebral cortex,
and midbrain afferents. Stimulation of one of these
afferent pathways can activate the sensation of vom-
iting via cholinergic (muscarinic), dopaminergic,
histaminergic, or serotonergic receptors (8).
Traditionally, the most common anti-emetics used
to treat PONV include serotonin 5 -hydroxytryp-
tamine type 3 antagonists such as ondansetron, cor-
ticosteroids, like dexamethasone, or droperidol,
which is a neuroleptic. However, these anti-emetics
are not completely reliable and only reduce the in-
cidence of PONV by26% (5).
Neurokinin-1 (NK1) receptors are found in gas-
trointenstinal vagal afferents and within the central
nervous system vomiting reflex pathways. NK1 re-
ceptors are activated by Substance P, which is a
regulatory peptide and preferred endogenous ligand
(9). NK1 receptor antagonism acts both at the pe-
ripheral and central levels and has been shown to
decrease PONV when administered preoperatively
for non-laparoscopic procedures (10, 11). However,
incidence of PONV is significantly lower in non-
laparoscopic procedures. As a result, we investigated
whether NK1 antagonism can effectively diminish
PONV in patients undergoing laparoscopic gyneco-
logical surgery.
METHODS
Data were collected at Tokushima University Hos-
pital (Tokushima, Japan) and the study protocol was
approved by the Human Research Ethics Committee
of the University of Tokushima. Sixty four female pa-
tients between the ages of 20-70 years old, ASA
physical state of I-II, who were undergoing elective
laparoscopic gynecologic surgical procedures with
general anesthesia were enrolled. Exclusion crite-
ria included : obesity (BMI33), pregnancy, steroid
use, abnormal liver or renal function, and neuronal
disease. All patients gave written informed consent.
All patients were questioned about previous PONV,
motion sickness, state of menstrural cycle, and
smoking state and history. Patients were random-
ized into two groups : NK1 group which received
an oral NK1 antagonist, aprepitant at 80 mg, and a
control that did not receive any anti-emetic.
Aprepitant was administered 180 mins before in-
duction of anesthesia. Premedication were not re-
ceived and standard monitoring were used, includ-
ing electrocardiography, noninvasive blood pressure,
pulse oximetry, and capnography. Induction and
neuromuscular blockade was accomplished with 0.3-
0.5 μg/kg/min remifentanil, 4 mg/kg thiamylal,
and 0.8 mg/kg rocuronium intravenously. Anesthe-
sia was maintained with 0.2-0.3 μg/kg/min remifen-
tanil and 1.0 minimum alveolar anesthetic concen-
tration sevoflurane. Rocuronium were injected 0.2
mg/kg every 45-60 mins.
Laparoscopies were performed with CO2 insuffla-
tion to a pneumoperitoneal pressure of 8 mmHg.
Neostigmine 1.0 mg and atropine 0.5 mg were used
for reversal and 1.0 mg/kg flurbiprofen axetil was
administered 15-30 mins before the end of surgery.
Nitrous oxide and morphine were not a used dur-
ing the procedure. Patients requiring postoperative
rescue antiemetics, were administered metoclopra-
mide, analgesic adjuncts 25 mg diclofenac sodium
SUP, or 15 mg pentazocine i.v. The types of analge-
sic adjuncts were chosen by the gynecologist.
Efficacy was assessed in 2 and 24 hours after sur-
gery. Primary and secondary endpoints were ana-
lyzed for the time intervals 0-2 hours (acute phase)
and 2-24 hours (delayed phase). The extent of nau-
sea was assessed by 4-point scale, which patients
rated nausea from 0 to 3 (0 : no nausea, 1 : mild
nausea, 2 : moderate nausea, and 3 : severe nausea)
as well as vomiting. Patient pain was recorded with
the visual analog scale (VAS) and patient analgesic
demand was also recorded.
STATISTICS
All results were analyzed with Graphpad Prism
5.0 software (La Jolla, CA) and are expressed as
meanSD. The means of each group were analyzed
by unpaired student’s t-test. Contingency tables
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were analyzed with Fisher’s exact tests. Statistical
significance was set at P0.05 for all tests.
RESULTS
Sixty four total patients were enrolled, but only 60
patients participated in the study. Four patients with-
drew due to either changes in the surgical proce-
dure from laparoscopic to laparotomy, changes in
anesthesia to propofol, and one patient decided not
to receive aprepitant after enrolling.
Thirty patients were in each group and the mean
ages for the control group and NK1 group were in-
significant at 38 and 35 years, respectively. There
were no significance between patient height or
weight and both groups had relatively similar ASA
physical states and risk factors for PONV (Table 1).
Furthermore, patients in both groups had similar
menstrual cycle phases. All patients tolerated aprepi-
tant without any adverse effects.
Surgical/anesthetic values throughout the proce-
dure also remained insignificant between control
and NK1 groups (Table 2). Duration of anesthesia,
length of procedure, patient blood loss, and infused
fluid volume were all similar. Additionally, similar
doses of remifentanil and rocuronium were used
in both groups.
PONV incidence at acute phase was present in
both control and NK1 groups and was 63% and 43%,
respectively. However, nausea, vomiting, and the
use of a rescue anti-emetic were less in the NK1
group all though no significance was observed
(Table 3). Furthermore, the severity of nausea was
Table 1. Patients Demographics
Control group NK1 group
Patients n=30 n=30
Age, yr (meanSD) 3813 3511
Height, cm (meanSD) 1575 1596
Weight, kg (meanSD) 537 548
ASA Physical state I/II, (n) 21/9 24/6
Risk factor
Tobacco use (n) 4 6
History of motion sickness/PONV (n) 14 13
Phase of menstrual cycle (n)
Follicular 13 15
Luteal 12 13
Postmenopause 5 2
Data are presented as number of patients or meanSD.
Table 2. Surgery/anesthesia values
Control group NK1 group
Duration of anesthesia, min 18059 17345
Duration of surgery, min 13052 12543
Anesthetics (meanSD)
Remifentanil, mg 3.12.0 2.61.1
Rocuronium, mg 52.811.9 56.312.5
Type of surgery (n)
Ovarian cystectomy/tumorectomy 24 21
Adhesiolysis 1 4
Myomectomy 3 1
Laparoscopic assisted vaginal hysterectomy 1 3
Salpingostomy 1 1
Temperature,(meanSD) 36.50.4 36.60.4
Blood loss, ml (meanSD) 2552 3967
Fluid volume, ml (meanSD) 1114318 1051247
Data are presented as number of patients or meanSD.
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significantly less in the NK1 group with the major-
ity of scores less than 1 (Table 3 and Figure 1).
At delayed phase PONV was present in the con-
trol group, but was absent in the NK1 group (27%
and 0%, respectively). Furthermore, vomiting, and
the use of a rescue anti-emetic were less in the NK1
group (Table 3). Nausea intensity was significantly
less prevalent/absent in the NK1 group whereas the
control group still had patients in all nausea scores
(Figure 2).
VAS pain scales were not significantly different
at acute or delayed phase. However, the amount of
pain medication required by patients was signifi-
cantly less for diclofenac and pentazocine in the
NK1 group suggesting greater pain tolerance or less
physical pain (Table 4).
Table 3. Postoperative nausea and vomiting
Control group NK1 group
Acute phase (0-2 hours)
Postoperative nausea and/or vomiting 19 13
Nausea 19 12
Low nausea severity (nausea score=0 or 1) 17 25 *
Vomiting (no. of episodes/no. of patients) 9/4 1/1
Rescue Anti -emetic 6 1
Delayed phase (2-24 hours)
Postoperative nausea and/or vomiting 8 0 *
Nausea 8 0 *
Low nausea severity (nausea score=0 or 1) 28 30
Vomiting (no. of episodes/no. of patients) 3/2 0/0
Rescue Anti -emetic 3 0
Data are presented as absolute values. *P0.05 vs. Control group. Nausea scores were assessed by patients rated nausea from 0
(no nausea) to 3 (severe nausea).
Figure 1. Patient nausea level between 0-2 hours. The severity
of nausea was recorded using the following scale : nausea score :
0=no nausea ; 1=mild nausea ; 2=moderate nausea ; 3=severe
nausea.
Figure 2. Patient nausea level between 2-24 hours. The sever-
ity of nausea was recorded using the following scale : nausea
score : 0=no nausea ; 1=mild nausea ; 2=moderate nausea ; 3=
severe nausea.
Table 4. Postoperative pain data
Control group NK1 group
VAS Pain scale (meanSD)
Acute phase (0-2 hours) 6.02.4 5.42.5
Delayed phase (2-24 hours) 3.72.5 3.02.1
Postoperative medication, mg (meanSD)
Diclofenac 20.818.7 10.413.2 *
Pentazocine 7.08.1 3.06.1 *
VAS=visual analog scale (0=no pain to 10=the worst pain imaginable).
*P0.05 vs. Control group.
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DISCUSSION
These results show that NK1 receptor blockade
via , aprepitant can effectively decrease PONV in
laparoscopic gynecological procedures. Further-
more, these results suggest that NK1 blockade can
hasten recovery from PONV as well as decrease
the amount of pain medication required following
surgery. These results suggest that NK1 blockade
may be advantageous in suppressing PONV and
may be beneficial if administered prior to these type
of procedures.
Aprepitant has traditionally been used in the treat-
ment of cancer chemotherapy induced nausea and
vomiting (12). Recently, aprepitant has also been
shown to be highly efficient in treating PONV. In
clinical trials, aprepitant was shown to be even more
efficacious than traditional medications such as on-
dansetron (10, 11). However, these trials mainly in-
vestigated non-laparoscopic procedures, which have
a significantly lower incidence of PONV. Further-
more, these trials did not investigate the effect of
NK1 antagonism on post-operative pain, which has
been effective in animal models, but has been diffi-
cult to translate into humans (13). Aprepitant has
been shown to be ineffective in healthy human mod-
els for electrical hyperalgesia (14). In our results
VAS pain scores were not significant between NK1
and control groups, however, we found that the
total amount of pain medication administered was
significantly decreased in NK1 groups for diclofenac
and pentazocine suggesting an increased pain tol-
erance and decreased need for analgesia.
Substance P (SP) is one of neurotransmitters
found in both the central and peripheral nervous
systems, and it is known that after binding to the
NK1 receptors, SP regulates many biological func-
tions in the central nervous system such as emo-
tional behavior, stress, depression, and anxiety (14).
SP has been also implicated in inflammation and
pain (8). By contrast, it is known that NK1 recep-
tor antagonists specifically inhibit these biological
functions mediated by SP after binding to NK1 re-
ceptors in animal tests (13, 14). However, NK1 re-
ceptor antagonists failed to efficacy in clinical trials
in humans (13, 14). In our study, aprepitant was
significantly decreased the amount of postoperative
analgesic rescue adjuncts. This is shown NK1 re-
ceptor antagonists might be effective analgesics in
humans.
Control patients only had a 63% incidence for
PONV which is much lower than the previously
reported 80% (6). Furthermore, aprepitant was only
effective in about 60% of patients at acute phase but
by delayed phase was effective in all of the patients.
Interestingly, at delayed phase roughly 73% of con-
trol patients were also symptom-free suggesting that
PONV quickly resolves without intervention in our
patient population. Diemunsch et al (10) stated that
a 40 mg dose was effective in 64% of their patients,
but their results may have overestimated the effect
of aprepitant as they did not have a control group
that did not receive any medication. Our current re-
sults also suggest that aprepitant may also hasten
the recovery from PONV as all patients in the NK1
group were symptom free by 24 hours.
Aprepitant can have serious side effects as it is
non-selective in NK1 receptor blockade. These ef-
fects can include asthma, anxiety, arthritis, migraine,
schizophrenia, glaucoma, neural injury and stroke
(8). Furthermore, a potential side effect of aprepi-
tant is nausea and vomiting. Although vomiting in
the NK1 group was a result from PONV or from the
aprepitant itself.
There are some limitations in our results. Use of
flurbiprofen axetil cause nausea and vomiting in ap-
proximately 0.5-5%, it may be effective for PONV.
However, patients in both groups were administered
flurbiprofen axetil, it was not detected an effect of
flurbiprofen axetil for PONV.
For postoperative rescue antiemetics, patients
were administered pentazocine. Pentazocine oc-
curred nausea and vomiting itself. Compared with
other opioids, nausea and vomiting associated with
pentazocine was generally tolerated.
In conclusion, our study investigated the use of
aprepitant in PONV laparoscopic gynecological pro-
cedures. Our results, suggest that aprepitant can
effectively lower PONV and also hasten recovery.
Furthermore, our data suggests that aprepitant may
have partial analgesic effects by increasing pain tol-
erance as pain medication doses were significantly
lower in NK1 treated groups.
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